Background. Pneumococcal polysaccharide/ protein conjugate vaccines (PnCV) are immunogenic and effective in infancy. However, an addition to the nine currently recommended vaccine injections during the first year of life of African children may be a deterrent to participation in a PnCV program. Thus we have evaluated the safety and immunogenicity of a 9-valent PnCV (Wyeth Lederle Pediatrics and Vaccines) mixed with diphtheria, tetanus toxoid, cell pertussis and Haemophilus influenzae type b (TET-RAMUNE).
INTRODUCTION
The first multivalent pneumococcal conjugate vaccine was licensed in the United States in February 2000. 1 There are Ͼ90 serotypes of the pneumococcus, many of which cause disease in adults and children. In The Gambia 9 serotypes are responsible for ϳ80 to 85% of cases of invasive disease in young children. 2 Preliminary studies in The Gambia evaluated the safety and immunogenicity of a pentavalent pneumococcal polysaccharide conjugated to CRM 197 (cross-reactive variant of diphtheria toxoid) 3 and the ability of this vaccine to induce immunologic priming for a subsequent response to pneumococcal polysaccharide. 4 These 5 serotypes account for only ϳ60% of invasive pneumococcal disease in Gambian children. 3 Furthermore the Expanded Program of Immunization (EPI) for children already offers 9 injections of various vaccines during the first year of life, and an additional 3 injections might be a disincentive for participation in the vaccination program. Combination of vaccines should make administration easier, less expensive and more acceptable to parents.
For these reasons we evaluated the safety and immunogenicity of a 9-valent pneumococcal conjugate vaccine given in combination with TETRAMUNE administered simultaneously at different sites or mixed and administered as a single injection.
The primary objective of this study was to demonstrate that mixing a pneumococcal conjugate vaccine with TETRAMUNE does not unacceptably (1) increase the incidence of side effects, (2) depress the immune response to Hib polyribosylribitol phosphate (PRP) or (3) depress the immune response to any of the components of diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine (DTP), compared with TETRAMUNE immunization alone. The secondary objective was to show that mixing does not unacceptably depress the immune response to the polysaccharide components of the pneumococcal conjugate vaccine compared with separate but simultaneous immunization with TETRAMUNE and pneumococcal polysaccharide/protein conjugate vaccine (PnCV).
SUBJECTS AND METHODS
The ethics committees of the Institute of Child Health London, the London School of Hygiene and Tropical Medicine and The Gambian Government/ Medical Research Council approved the study protocol. Infants were recruited from the population who presented for routine vaccination at the Maternal Child Health clinics at Basse, Bansang and Garrowol in Upper River Division of The Gambia. Verbal and written informed consent in the preferred language was obtained from the parents or guardian of the study infants.
Vaccines. Wyeth-Lederle Pediatrics and Vaccine manufactured the pneumococcal conjugate vaccine used in the study. It was prepared in a lyophilized form and contained 2 g of types 1, 4, 5, 9V, 14, 19F and 23F pneumococcal polysaccharides; 2 g of type 18C oligosaccharide; and 4 g of type 6B polysaccharide. Each polysaccharide or oligosaccharide was coupled independently to CRM197, a nontoxic mutant of diphtheria toxoid, to give ϳ20 g of CRM 197 per dose. TET-RAMUNE contained in each 0.5-ml dose ϳ12.5 limes flocculation units (Lf) of diphtheria toxoid, 5 Lf of tetanus toxoid, 4 protective units of whole cell pertussis vaccine as determined in a mouse protection assay and 1 g of Hib oligosaccharide conjugated to 25 g of CRM 197 . The placebo was physically indistinguishable from pneumococcal conjugate vaccine and was supplied in single dose lyophilized vials that required reconstitution of the contents with NaCl-sucrose solution. TET-RAMUNE was used as diluent for the placebo and PnCV. Diluent for reconstitution of pneumococcal conjugate vaccine, when it was administered separately, was saline containing aluminum phosphate. All vaccines were reconstituted just before administration.
Immunization. Randomization of vaccine administration was done based on a previously prepared computerized randomization list. Participants were individually randomized in a double-blind manner to one of three groups as follows: control group, lyophilized placebo reconstituted in TETRAMUNE administered as a single injection in the right thigh; separate group, TETRAMUNE administered as a single injection to the right thigh and pneumococcal conjugate vaccine reconstituted in saline/sucrose diluent administered as a separate injection into the left thigh; combined group, pneumococcal conjugate vaccine reconstituted in TET-RAMUNE and administered as a single injection into the right thigh.
Subjects were immunized according to the current EPI schedule at 2, 3 and 4 months with oral polio vaccine and with hepatitis B vaccine given at 1, 2 and 4 months of age. When Calmette-Guérin bacillus (BCG) was not administered at birth, administration of the study vaccine and BCG was separated by an interval of at least 2 weeks.
Reactogenicity. All infants were observed for 30 min after immunization at the clinics for immediate adverse reactions. A field assistant visited infants on Days 2 and 7 after each vaccine dose to administer a side effects questionnaire to the parents/guardian and to examine the baby for fever, tenderness, swelling and redness at the site of injection(s). The length and breadth of any swelling or redness at the site of injection were measured. During the study spontaneous clinic visits to the Medical Research Council clinic at Basse were encouraged for the treatment of minor complaints.
Antibody determination. Blood for antibody assays was drawn immediately pre-Dose 1 (age 2 months) and 1 month post-Dose 3 (age 5 months). Serum was separated within 2 h of collection and stored at Ϫ20°C. 5 IgG antibodies to pertussis (pertussis toxin, filamentous hemagglutinin, fimbriae 2/3), diphtheria toxin, tetanus toxoid and Hib-PRP antigens were measured with standardized enzyme-linked immunosorbent assays. 6 -8 Data management and analysis. Data management and analysis were performed using Epi-Info computer software, Version 6 (Centers for Disease Control and Prevention, Atlanta, GA) and Version 6 (SAS Institute, Cary, NC). Analysis of serum antibodies was based on logarithms of the antibody concentrations. Geometric mean concentrations of antibody (GMC) and 95% confidence intervals were determined for antibody to each antigen by vaccine group. The confidence intervals were based on normal distributions on the logarithmic scale. Comparisons of the GMCs between the groups were made according to Student's t test. Comparisons of systemic and local reactions were made using the Fisher exact test. All statistical tests were performed with two sided P values and a type 1 error rate ␣ Ͻ 0.05.
Sample size calculations were determined by the primary objective of the study, which was to demonstrate that the response rate to PRP antigen in recipients of the mixture of vaccines (the combined group) was not lower by 10% or more than the response rate in recipients of TETRAMUNE alone (control group). It was assumed that the true response rates would be identical in the two groups, and sample size was calculated by the likelihood score approach described by Farrington and Manning. 9 The sample sizes were chosen to have at least 80% power to detect an upper limit of Ͻ0.10 for two sided 90% confidence limits for the difference between response rates in Group 1 vs. Group 3 (equivalent to rejection of the null hypothesis of a difference of Ն 0.1 at a one sided 5% significance level). The resulting sample size was 163 per group. More infants were enrolled into each group to allow for failure to obtain necessary assays, loss to follow-up and noncompletion of randomized subjects. Geometric mean concentrations for pneumococcal serotypespecific IgG antibodies were compared between the vaccine and control groups by Student's t test.
RESULTS

Study profile.
We enrolled 590 infants into the study when they were age 2 months. Group 1 comprised 197 infants randomized to receive placebo reconstituted in TETRAMUNE and administered as a single injection into the right thigh. Group 2, the separate group, comprised 196 infants randomized to receive pneumococcal conjugate vaccine reconstituted in saline diluent given into the left thigh and TETRAMUNE administered into the right thigh. Group 3, the combined group, comprised 197 infants randomized to receive pneumococcal conjugate vaccine reconstituted in TETRAMUNE as a single injection into the right thigh.
Of the 590 randomized infants, 5 did not receive the second dose of the study vaccine; 4 parents withdrew consent and 1 received DTP from a Maternal Child Health clinic outside the study area, thus making them ineligible for further participation in the trial. Therefore 585 received the second dose of study vaccines. Of these 585 infants 1 died (unrelated to study protocol), 4 traveled outside the study area and 5 parents withdrew consent for continuation in the study. Thus 575 infants were offered and received the third dose of study vaccines. After completion of vaccination 1 infant died of severe malaria, 7 mothers refused a postvaccination blood sample from their infants and 4 traveled outside the study area. Therefore 563 infants (95%) had postvaccination sera drawn. Of these 11 had vaccine window violations, 10 had serum window violations and 18 violated the BCG vaccine window. This left 524 valid paired sera for serologic and immunogenicity analysis as set out in the protocol.
Adverse events. Most infants were available for observation on both Days 2 and 7. At the Day 2 visit information was elicited about the first 24 h after vaccination (Day 1) and about the current status of the infant (Day 2). After vaccination there were no immediate adverse reactions. Local and systemic adverse events were observed and recorded when infants were visited at home on Days 2 and 7. The reactions observed were expected ones, and all resolved spontaneously. The symptoms elicited from the mother or guardian by direct questioning and results of direct observations are summarized in Table 1 . A report of "feeling hot" on Day 1 after vaccination was frequent in all vaccine groups. However, there was a trend toward a decrease in the frequency of this complaint with later doses of study vaccine. The difference in the frequency of events after the first dose of vaccine was statistically different from that seen after the third dose (t test; P ϭ 0.004 for the control group, P ϭ 0.003 for the separate group and P ϭ 0.014 for the combined group). Temperature measurements were taken on Days 2 and 7 (Table 1) . Overall, febrile reactions were infrequent. Two infants had a temperature above 39°C after the third dose of vaccine; these infants responded promptly to antipyretic treatment.
Local swelling at the site of injection was encountered more frequently at the site of administration of TETRAMUNE than at the site of administration of PnCV (P Ͻ 0.00001 for Doses 1 and 2 and P Ͻ 0.0009 for Dose 3). Local swelling at the site of administration of TETRAMUNE mixed with PnCV was comparable with that observed for TETRAMUNE alone (Table 2) . Point tenderness at the site of injection was also significantly more frequent at the site of TET-RAMUNE injection than at the site of PnCV injection for each vaccine dose (P Ͻ 0.00001). Redness at the site of injection was rarely observed (data not shown).
All study participants were followed up for morbid events from the time of enrollment to the time of the post vaccination blood drawing. Spontaneous outpatient visits were made by mothers/guardians when their infants had any medical problems. These infants were seen initially by a nurse and then referred to a study physician when a diagnosis was not obvious or when a child required hospitalization. All visits were documented on the infant welfare card, which contained immunization and growth record charts. Morbid events that required hospitalization were classified as serious and life-threatening if the clinical condition at presentation was critical. Serious adverse events that required hospitalization were common acute infectious illnesses of Gambian infants, and these were distributed evenly among the three vaccine groups.
Two subjects died during the surveillance period. One infant in the separate group died 22 days after the second dose of vaccine because of severe acute lower respiratory infection. A blood culture was sterile but a postmortem lung aspirate obtained immediately after death yielded Staphylococcus aureus. The second death occurred in an infant in the same group. This death (5) 16 (8) 154 (80) 12 (6) 10 (5) 163 (83) 14 (7) 18 ( (8) 19 (10) 132 (69) 10 (5) 10 (5) 123 (63) 12 (6) 16 (72) 45 (23) 115 (59) 54 (28) 94 (49) 24 (13) occurred outside a health facility 7 days after the third study vaccine dose. This death occurred during an outbreak of meningococcal disease in the region. Three independent physicians who were not involved with the study reviewed the postmortem information and concluded that death was not related to vaccination. Serology. Intention to treat analysis and per protocol analysis of anti-PRP responses gave similar results. Sixteen infants did not achieve an anti-PRP antibody concentration of 0.5 g/ml or more postvaccination. Nine of these infants were from the control group, 3 from the separate group and 4 from the combined group. All these infants were given a fourth dose of TETRAMUNE but without further antibody studies.
Anti-PRP antibody responses were highest in the separate group (Table 3) . Comparison of responses between the control and combined groups showed that a significantly higher proportion of infants in the combined group achieved anti-PRP antibody concentrations of 1 g/ml or more (P ϭ 0.01). The geometric mean concentration of anti-PRP antibody was higher in the combined than in the control group, but this difference was not statistically significant (P ϭ 0.37).
The geometric mean concentration of anti-diphtheria toxoid antibody did not differ among the three groups (Table 4) . Overall five infants did not achieve a protective antibody concentration of 0.1 IU/ml. Three of the infants were from the separate group, including one who did not achieve protective anti-PRP antibody concentrations and one each from the control and combined groups. These infants were given a fourth dose of TETRAMUNE.
The geometric mean antibody concentration for antitetanus toxoid antibody was highest in the control group. Although the geometric mean concentration was significantly lower in the combined group than in the separate group (P ϭ 0.02), all children achieved protective antibody concentrations (Table 4) .
Geometric mean and 95% confidence intervals for serotype-specific pneumococcal polysaccharide antibody concentrations are presented in Table 5 . There was a trend for higher geometric mean concentrations in the combined than in the control groups for all serotypes, but this was significant only for serotypes 18C and 23F. Responses were highest for serotype 5 in all three groups.
DISCUSSION
Combination vaccines offer several advantages, particularly in resource-poor communities. These include reduction in the number of clinic visits, number of injections and injection sites, syringes, storage space and the trauma experienced by parent and infant. There may be safety and/or immunologic limitations to the number or type of vaccines that can be combined. In this study we evaluated the safety and immunogenicity of the composite antigens when TETRAMUNE (4 antigens) was coadministered with a 9-valent pneumococcal conjugate vaccine.
The combination of the 9-valent pneumococcal conjugate vaccine with TETRAMUNE was well-tolerated when administered in three doses to Gambian infants. The proportion of children who experienced local reac- tions was similar to that seen in previous studies of pneumococcal conjugate vaccines. 10, 11 Reports by mother or guardian of febrile reactions on the first day after vaccination were common in all vaccine groups, but only a few children had a documented temperature of 38°C or more 48 h after vaccination. Because all children received TETRAMUNE, it is not possible to ascertain whether these febrile episodes were attributable to PnCV, TETRAMUNE or a combination of the two vaccines. The proportion of children perceived by their parents as having fever did not differ among the three groups.
The response to Hib PRP was augmented by the coadministration of PnCV. This effect has been observed previously in a similar study done in Soweto, South Africa. 12 However, in Soweto this was associated with a diminution of response to the pneumococcal polysaccharide antigens. This contrasts with findings in our study in which we observed an increase in the serologic response to most of the pneumococcal polysaccharides included in the conjugate vaccine preparation when given with TETRAMUNE. The response to tetanus toxoid was attenuated by coadministration of TET-RAMUNE with PnCV, although all children achieved protective antibody titers. Every serotype contained in the pneumococcal conjugate vaccine was immunogenic, although the immunogenicity varied among serotypes. Serologic responses to eight of the nine pneumococcal polysaccharides were augmented by coadministration of TETRAMUNE, but differences between the groups achieved statistical significance only for serotypes 18C and 23F. The responses to the 9V conjugate were similar in the two groups.
This study evaluated the safety and immunogenicity of 13 antigens administered as a single injection; therefore some antigenic interaction is not unexpected. Dose-dependent carrier-induced suppression of Hib and tetanus antibody responses has been observed with pneumococcal vaccine conjugated to tetanus toxoid when administered concomitantly with diphtheria, tetanus toxoid, whole cell pertussis and H. influenzae type b conjugate vaccine and Hib-tetanus toxoid conjugate at 2, 4 and 6 months of age. Conversely enhancement of Hib and diphtheria responses has occurred when pneumococcal CRM197 conjugate vaccines were administered concomitantly with diphtheria, tetanus toxoid, whole cell pertussis and H. influenzae type b conjugate vaccine and oligosaccharide conjugate of H. influenzae type b at 2, 4 and 6 months of age. 13 The serotype-specific antibody concentrations required for protection against invasive pneumococcal disease are not known, but data from the recently concluded Kaiser Permanente efficacy trials suggest that these may be in the range of 0.15 to 1 g/ml.
1 In Africa, as in most developing countries, many factors can impact on clinical efficacy of this vaccine. Whether these antibody concentrations would offer any protection in the presence of the multiple infectious agents and the consequent immunosuppression often seen in developing countries can be determined only by an efficacy trial.
We conclude that mixing pneumococcal conjugate vaccine with TETRAMUNE does not increase the incidence of adverse events and does not depress immune response to Hib polyribosylribitol phosphate or depress significantly the immune response to any of the components of DTP vaccine compared with TETRAMUNE immunization alone. Furthermore mixing does not depress immune response to the polysaccharide components of the pneumococcal conjugate vaccine compared with separate but simultaneous immunization 
